logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Alder BioPharmaceuticals (ALDR)

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine Alder Also Reports Positive Phase 1 Data Supporting Quarterly Single Injection Dosing Strategy for ALD403 Alder BioPharmaceuticals (ALDR)  announced positive...

Read More

March 28, 2016

0

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine Alder Also Reports Positive Phase 1 Data Supporting Quarterly Single Injection Dosing Strategy for ALD403 Alder BioPharmaceuticals (ALDR)  announced positive...

Read More

March 28, 2016

0

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine Alder Also Reports Positive Phase 1 Data Supporting Quarterly Single Injection Dosing Strategy for ALD403 Alder BioPharmaceuticals (ALDR)  announced positive...

Read More

March 28, 2016

0

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis Story In May 2018 Amgen ( AMGN ) & Novartis ( NVS ) announced that their novel migraine drug Aimovig™ was granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically...

Read More

April 8, 2019

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis Story In May 2018 Amgen ( AMGN ) & Novartis ( NVS ) announced that their novel migraine drug Aimovig™ was granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically...

Read More

April 8, 2019

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis Story In May 2018 Amgen ( AMGN ) & Novartis ( NVS ) announced that their novel migraine drug Aimovig™ was granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically...

Read More

April 8, 2019

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

  • 1

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy